Matthew Lamkin
liked
Snap's share plunged on disappointing Q2 2022 earnings miss
Snap Inc. is a camera and social media company, founded on 2011. The main revenue of Snap comes from advertising with nearly 88% coming from the US. Snapchat, as its social networking platform, owns approximately 347 million daily active users.
Snap’s share price plummeted up to 30% following the company’s Q2 2022 results and it plans to slow hiring since it reckons with weakening growth on revenue.
Q2 2...
Snap Inc. is a camera and social media company, founded on 2011. The main revenue of Snap comes from advertising with nearly 88% coming from the US. Snapchat, as its social networking platform, owns approximately 347 million daily active users.
Snap’s share price plummeted up to 30% following the company’s Q2 2022 results and it plans to slow hiring since it reckons with weakening growth on revenue.
Q2 2...
![Snap Q2 2022 Earnings Snapshot](https://ussnsimg.moomoo.com/77777008/editor_image/0646ea79d8143720a8b3ebb0eadbc6e3.jpg/thumb)
32
3
Matthew Lamkin
commented on
$Ocugen(OCGN.US$ for those that follow me $Cocrystal Pharma(COCP.US$ will pop soon get in if you like what you see
4
5
Matthew Lamkin
commented on
$Ocugen(OCGN.US$ buy it soon ! it’s going to 16. up up up
2
3
$Brooklyn ImmunoTherapeutics Inc(BTX.US$ stock is dead.... microvision 2.0...
3
3
Matthew Lamkin
commented on
$Brooklyn ImmunoTherapeutics Inc(BTX.US$ 30 swing in less than 24 hours. wtf. hold people. this isnt how you get a stock to go up. thought we all wanted to make money. smdh. all day just sell sell sell. get a real job.
1
2
Matthew Lamkin
commented on
$Precipio(PRPO.US$ $Brooklyn ImmunoTherapeutics Inc(BTX.US$ BTX move in the making folks. This is the ground floor. 10mil less shares in the float than BTX. Could see over $100 here imo.
5